ORNIDYL
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORNIDYL is an injectable small-molecule NDA approved in 1990 by Sanofi. The specific indication and mechanism of action are not publicly detailed in available data, limiting assessment of therapeutic positioning.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; brand teams should expect resource optimization and potential transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature lifecycle stage and approaching LOE. Career roles on ORNIDYL are primarily defensive—managing decline, protecting market share, and optimizing remaining revenue.
Brand ManagerField Sales Representative
Worked on ORNIDYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.